VYOME HOLDINGS INC (HIND)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.74-1.93%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · HIND
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 4.3% |
| Our one-year growth estimate | diamond | 76.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 72.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
HIND — CEO transition
Dated 2026-08-28
CFO — Jerry Leonard: The filing discloses the appointment of an external fractional CFO, which is a new hire rather than a departure of a sitting executive.
Why it matters: The designation would mark progress for VT-1953 in a rare disease. A denial or long delay would leave this goal unmet.
Supportive ifThe FDA grants Orphan Drug Designation for VT-1953 in a public filing or company update.
Worry ifThe FDA denies the application, or the next company update says there is no decision.
Why it matters: The Phase 2 study showed better wound odor and pain, with no treatment-emergent side effects. A new study can test whether those results hold.
Supportive ifA later VT-1953 study reports a clear drop in wound odor or pain versus its control group. It reports no side effects that began during treatment.
Worry ifA later study finds no clear drop in wound odor or pain, or reports treatment-emergent side effects.
Why it matters: Vyome reported $7.9 million in cash at June 30 and remains loss-making. A sharp cash drop may raise pressure to seek funding.
Worry ifThe November 13 results report cash below $6 million, or disclose new share sales or debt.
Less concerning ifCash remains at or above $6 million, with no new debt or share sale disclosed.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$179 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $709 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,245 loss on $10,000 · 72.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.